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Abstract
Background: Her2 expression and amplification occurs in a significant subset of gastro-esophageal carcinomas.
Her2 is a client protein of molecular chaperones, e.g. heat shock protein (HSP) 90, rendering targeted therapies
against Her2/HSP90 an interesting approach. This study aimed to investigate the role and relationship of Her2 and
HSP90 in gastric and gastro-esophageal adenocarcinomas.
Material and Methods: Immunohistochemical determination of HSP90 and Her2 expression was performed on 347
primary resected tumors. Her2 amplification was additionally determined by fluorescence in situ hybridization for all
cases. Expression and amplification results were correlated with pathologic parameters (UICC pTNM category, tumor
grading) and survival.
Results: Elevated Her2 copy numbers were observed in 87 tumors, 21 of them showing amplification. 174 tumors
showed Her2 immunoreactivity/expression. HSP 90 immunoreactivity was found in 125 tumors. There was no
difference between gastric carcinomas and carcinomas of the gastroesophageal junction regarding Her2 or HSP90.
Both high HSP90 and Her2 expression/amplification were associated with earlier tumor stages (p<0.01), absence of
lymph node metastases (p<0.02) and Laurens intestinal type (p<0.001). HSP90 correlated with Her2 expression and
amplification (p<0.001 each). Expressions of HSP90 and Her2, but not Her2 amplification were associated with better
prognosis (p=0.02; p=0.004; p=0.802). Moreover, Her2 expression was an independent prognostic factor for overall
survival in the subgroup of gastric carcinoma patients (p=0.014) besides pT category, pN category and distant
metastases.
Conclusion: Her2 expression and gene amplification occurred in a significant subset of cases. Our results suggest a
favorable prognostic impact of Her2 expression. This warrants further investigations regarding the significance of
Her2 non-amplified tumors showing Her2 immunoreactivity and the definition of Her2 status in gastric cancers.
Moreover, the correlation of Her2 expression with the expression of Her2 chaperoning HSP90 may indicate a
synergistic regulation. Targeting HSP90 with or without Her2 may offer additional therapeutic options for gastric
carcinoma treatment.
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Introduction
Amplification and overexpression of Her2 occurs in a
significant number of gastroesophageal adenocarcinomas
[1–3]. Recently, Her2 targeted therapy with trastuzumab has
been introduced in the treatment of metastatic gastric
carcinomas and adenocarcinomas of the gastroesophageal
junction [4–7]. Her2 is a client protein of HSP90, a member of
the family of heat shock proteins (HSPs), which are considered
molecular chaperones, as they are responsible for the correct
folding of denatured or translated proteins [8,9]. It has been
suggested that HSP90 expression may also modulate the
effects of oncogenic Her2 [10], representing a potential
mechanism of resistance to Her2 directed drugs. On the other
hand, Hsp90 inhibitors may potentiate the effects of anti-cancer
drugs targeting client proteins of HSP90 [11]. In breast cancer,
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for example, additional targeting of HSP90 has been shown to
increase trastuzumab efficiency in vivo and in vitro [12,13].
Similar results have been published very recently as well for
gastric carcinoma [14]. The few existing ex vivo studies about
the impact of the expression and regulation of HSPs in gastric
cancer show conflicting results about the prognostic role of
HSP90 expression, but they describe a frequent
overexpression of this potentially targetable molecule [15–17].
Any possible relationship between HSP90 and Her2, however,
has not been investigated in this cancer entity to date.
The aim of the present study was to evaluate the relationship
between Her2 and HSP90 in gastric carcinomas and
carcinomas of the gastroesophageal junction, and its influence
on tumor biology and behavior.
Materials and Methods
1. Ethics statement
All patients gave written informed consent for the use of
additional molecular analysis at the time of operation. The
usage of human archival tissue for molecular analysis was
approved by the local Ethics Committee of the Faculty of
Medicine of the Technische Universität München.
2. Patients and tissues
We investigated formalin fixed, paraffin embedded (FFPE)
archival cancer tissue from 347 patients with primary resected
gastric carcinoma and carcinoma of the gastroesophageal
junction who underwent surgery between 1995 and 2005 at the
Klinikum Rechts der Isar of the Technische Universität
München (Germany). None of the patients had received pre- or
perioperative neoadjuvant treatment.
Two hundred twenty-one of the patients were male (63.7%)
and 126 female (36.3%), with a median age of 69 years (range:
29 to 100). Median overall survival (OS) of all patients was 19
months (95% CI 14-23 months). Seventy-three tumors (21.0%)
were adenocarcinomas of the gastroesophageal junction, and
274 were gastric carcinomas (79%). Most tumors showed an
intestinal phenotype (153, 44.1%). Sixty tumors were mixed
type carcinomas according to Lauren (17.3%), 111 showed a
diffuse phenotype (32%) and 23 were unclassifiable (6.6%).
Tumor grading was G1 (well differentiated) in 1 case (0.3%),
G2 (moderately differentiated) in 54 cases (15.6%) and G3-G4
(poorly differentiated) in 292 cases (84.1%). Complete
resection was achieved in 197 patients (56.8%, R0). For the
purpose of this study, all tumors were reclassified according to
the current UICC TNM-classification [18]. We included tumors
of all TNM categories. The clinicopathologic characteristics of
the collective are given in table 1. The complete dataset of the
collective including the results of the immunohistochemical and
in situ hybridization analysis is given as supplemental data file
(Table S1).
3. Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue.
Preparation of tissue microarrays (TMA) was performed as
described before, generating triplicate cores from randomly
selected tumor areas with a diameter of 1.0 mm each [19]. The
paraffin blocks were freshly cut (3 µm). Slides were dewaxed
and rehydrated, with subsequent heat-induced antigen retrieval
using 10 mM citrate buffer, pH 6, H2O2 blocking using 3% H2O2
in aqua destillata and avidin biotin blocking (Avidin/Biotin
blocking kit, Vector Laboratories, Inc., Burlingame, CA, USA).
The sections were then incubated with antibodies for HSP90
(Abcam, Cambridge, UK) and Her2 (DAKO, Glostrup, DK).
Positive and negative controls were included in each reaction.
Positive HSP90 staining was defined as cytoplasmic staining
of ≥10% of carcinoma cells (Figure 1). Her2 expression on
TMA cores was assessed according to published
recommendations for routine Her2 evaluation in gastric
carcinoma, including the slight modifications recommended for
the use on biopsies [20]: In short, immunohistochemistry 3+
staining was defined as any membranous staining visible at low
magnification (objective × 2.5–5), immunohistochemistry 2+
was defined as membranous staining visible at × 10–20
magnification, and immunohistochemistry 1+ staining was
defined as weak membranous staining visible only with × 40
magnification. Cases with no visible membranous reactivity
were classified as negative (Figure 1).
Evaluation of HSP90 and Her2 expression was performed by
two independent observers (SB, RL or AW) and discrepancies
were discussed at a multihead microscope to gain a final
consent. Only cores with technically unequivocal staining
results and sufficient tumor content (>50 tumor cells) were
used for final analysis.
Table 1. Clinicopathologic parameters.
Characteristics  N %
Gender Female 126 36.3
 Male 221 63.7
 
Localisation Gastroesophageal junction 73 21.0
 Stomach 274 79.0
 
pT category pT1 24 6.9
 pT2 31 8.9
 pT3 113 32.6
 pT4 179 51.6
 
pN category pN0 84 24.2
 pN1 52 14.9
 pN2 51 14.7
 pN3a 118 34.0
 pN3b 42 12.1
 
cM category absent 259 74.6
 present 88 25.4
 
Grading G1-G2 55 15.9
 G3-G4 292 84.1
 
Lauren´s type intestinal 153 44.1
 non-intestinal 194 55.9
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4. Fluorescence in situ Hybridization
All cases were also tested for Her2 amplification by
fluorescence in situ hybridization (FISH), irrespective of prior
immunohistochemical Her2 results. An assay with
fluorescence-labeled locus-specific DNA probes for Her2 and
chromosome-17 centromeric α-satellite (Chrombios) was
hybridized onto 4 μm TMA sections as described before
[21,22]. FISH signal evaluation was performed by visual
counting using an epifluorescence microscope (Zeiss Axioplan
2, Carl Zeiss Microimaging GmbH) according to standard
procedures as recommended in literature [21]. At least 50
invasive tumor cells per case with a minimum of one signal for
Her2 gene and centromere(CEP)-17 were randomly selected,
and the mean Her2 and CEP17 count was calculated. Cases
were classified as amplified when Her2/CEP17 quotient was
≥2. Cases with simultaneously elevated Her2 and CEP17
counts were assigned as polysome when the Her2/CEP17
quotient was <2 [21] (Figure 2).
5. Statistical Analysis
For statistical analysis, IBM SPSS 21.0 Statistics statistical
software (SPSS Inc., Chicago, IL, USA) was used.
Associations between immunohistochemical expression
patterns, results of FISH analysis and pathological features
were given in crosstabs and were evaluated with X² and
Fisher’s exact test. Survival analysis was performed using
Kaplan-Meier estimates, log rank tests and Cox’s proportional
hazards regression analysis. All tests were 2-sided, and the
significance level was set at 0.05.
Results
1. Her2 expression and amplification
Three hundred thirty-six cases were evaluable for
membranous Her2 expression and all 347 cases for Her2
amplification. The majority of tumors showed Her2 expression
(174 cases; 51.8%), which was weak in 96 cases (1+; 28.6%),
moderate in 43 (2+; 12.4%), and strong in 35 tumor samples
(3+; 10.1%; Figure 1 A–C Table 2). Eleven cases could not be
evaluated by immunohistochemistry using the inclusion criteria
given above.
Fluorescence in situ hybridization analysis showed elevated
Her2 copy numbers in 87 tumors, 66 of them were polysome
(19%) and 21 patients (6.1%) showed Her2 amplification as
defined by a Her2/CEP17 ratio ≥2 (Figure 2 Table 2). Two
hundred sixty cases (74.9%) showed no Her2 amplification.
Correlation was strong between Her2 expression and
amplification (p<0.001, Table 2). All Her2 amplified cases
showed membranous Her2 expression, which was strong (3+)
in 61,9%, and contrasted the predominantly weak Her2
expression in polysome tumors. None of the
immunohistochemically Her2-negative (score 0) tumors were
Figure 1.  Her2 and HSP90 expression in gastric adenocarcinoma.  Gastric adenocarcinoma with (A) negative, (B) score 1+, (C)
score 3+ Her2 expression; (D) negative HSP90, (E) low HSP90 and (F) high HSP90 expression.
doi: 10.1371/journal.pone.0069098.g001
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Her2 amplified; however, 31 tumors had elevated Her2 copy
numbers (polysomy). Moreover, a significant number of Her2
expressing tumors (3+; 22/35; 63%) failed to show Her2
amplification (17 disome, 5 polysome). Additionally, 24 cases
with weak immunostaining (score 1+) had elevated Her2 copy
numbers, with seven of them showing Her2 amplification
(Table 2).
Applying the current FDA and EMEA algorithm, which
defines Her2 positivity as either immunohistochemical score 3+
or score 2+ validated by Her2 amplification assessment, 300
patients (89.3%) would have been considered Her2 negative,
and 36 (10.7%) as Her2 positive [20].
2. HSP90 expression
Of the 323 cases evaluable for HSP90 expression,
immunoreactivity was found in 125 tumors (38.7%). Only 6
cases (1.8%) showed a strong reaction against HSP90 versus
a weak cytoplasmic staining in the other positive cases (Figure
1 D–F). In 24 cases no valid immunohistochemical analysis for
HSP90 was possible, due to technical reasons.
3. Association between Her2 and HSP90
There was no difference between gastric carcinomas and
carcinomas of the gastroesophageal junction regarding Her2 or
HSP90. HSP90 expression correlated with Her2 expression
and Her2-status according to FDA and EMEA (see chapter
3.1.; p<0.001 each; Table 3), but not with Her2 amplification
alone (p=0.067).
4. Clinicopathological parameters and survival analysis
HSP90, Her2 expression and Her2 status according to FDA
and EMEA were associated with lower local tumor burden,
absence of lymph node metastases, better tumor differentiation
(grading), and intestinal phenotype according to Lauren (p
values see Tables 4 and 5). No such associations could be
demonstrated evaluating Her2 amplification alone.
Expression of HSP90 (p=0.02) and Her2 (score 1+, 2+ and
3+; p=0.004), but not Her2 status according to the FDA/EMEA
(p=0.502), Her2 amplification alone (p=0.802) or elevated Her2
copy numbers (p=0.813) were associated with better prognosis
in univariate analysis (Figures 3 and 4). Additional prognostic
factors were UICC pT category (p<0.001), presence of lymph
node or distant metastases at the time of surgery (p<0.001
Table 2. Comparison between Her2 immunohistochemistry
and FISH (p<0.001).
 Her2IHC Total
 0 1+ 2+ 3+  
Her2FISH Negative (n=260) 131 72 31 17 251
 Polysomy (n=66) 31 17 11 5 64
 Amplification (n=21) 0 7 1 13 21
Total  162 96 43 35 336
Table 3. Association between HSP90 expression and Her2
expression and Her2 status according to FDA/EMEA
(p<0.001 each).
 Her2 expression  Her2 status
 negative positive (*)  negative positive (**)
HSP90
(n=323)
Negative
(n=198) 112 81  182 11
 Positive(n=125) 39 85  100 24
Total  151 166  282 35
*score 1+,2+,3+; **according to the FDA/EMEA
Figure 2.  Fluorescence in situ analysis of Her2.  (A) Disomy and (B) high level Her2 amplification.
doi: 10.1371/journal.pone.0069098.g002
HSP90 and Her2 in Gastric/Gastroesophageal Cancer
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e69098
Table 4. HSP90 expression and pathological parameters.
factor  HSP90  
  neg pos p-value
pT category pT1 4 19 p<0.001
 pT2 16 14  
 pT3 59 45  
 pT4 119 47  
     
pN category pN0 41 39 p=0.024
 pN1 24 24  
 pN2 32 16  
 pN3 101 46  
     
cM category absent 138 103 p=0.012
 present 60 22  
     
Grading G1-G2 25 29 p=0.025
 G3-G4 173 96  
     
Lauren intestinal 65 84 p<0.001
 non-int. 131 40  
Table 5. Her2 expression and Her2 status and pathological
parameters.
factor  
Her2
expression   Her2 status 
  neg pos (*) p-value  neg
pos
(**) p-value
pT
category pT1 5 19 p=0.005  16 8 p=0.002
 pT2 11 20   27 4  
 pT3 51 58   100 9  
 pT4 95 77   157 15  
 
pN
category pN0 30 51
p=0.108
(p=0.014)#  67 14
p=0.128
(p=0.038)#
 pN1 24 27   47 4  
 pN2 22 27   42 7  
 pN3 86 69   144 11  
 
cM
category absent 115 138 p=0.1  224 29 p=0.542
 present 47 36   76 7  
 
Grading G1-G2 14 41 p<0.001  37 18 p<0.001
 G3-G4 148 133   263 18  
 
Lauren intestinal 48 101 p<0.001  120 29 p<0.001
 non-int. 112 72   178 6  
* Immunohistochemical score 1+,2+,3+; **according to the FDA and EMEA; #for
pNneg vs. pNpos
each), resection status (p<0.001), younger age at the time of
the operation (p=0.024) and intestinal phenotype according to
Lauren (p<0.001). Grading (tumor differentiation) or localization
(proximal versus distal) had no impact on overall survival.
However, HSP90 or Her2 were not independent prognostic
factors in multivariate analysis in the whole collective. When
analyzing the large group of gastric cancer patients separately
though (n=274), presence of any Her2 immunoreactivity (score
1+, 2+ and 3+) emerged as an independent prognostic factor
for overall survival (p=0.014) besides pT category, pN category
and distant metastases (Table 6). The independent prognostic
role of Her2 expression (p=0.024), pT, pN and distant
metastases was retained in the subgroup of non-intestinal type
tumors (Table 7). Contrary, Her2 expression was not an
independent prognostic factor in to the subgroup of purely
intestinal type tumors.
Discussion
Gastric carcinomas and adenocarcinomas of the
gastroesophageal junction have been shown to express Her2
in a significant number of cases, rendering it a possible
valuable molecule for molecular targeting [1–4,7,20]. However,
there is a high diversity of the definition of Her2 status in gastric
cancer in literature. The definition depends on the detection
methods that are used (immunohistochemistry; in situ
hybridization) and on the interpretation of the results of the
staining and hybridization. For immunohistochemistry, where
the proposals of Hofmann and Ruschoff [20,23] are widely
accepted as evaluation standard, usually a score 3+ is
considered as overexpression. A score of 2+ is considered as
equivocal, and a score of 1+ and 0 is considered as negative.
However, there are some studies, which consider also weak
immunostaining (1+) as a positive reaction [3]. In our study we
based the description of Her2 expression (1+, 2+ and 3+) on
the results of the survival analysis, where the prognostic impact
of a weak immunoreactivity (i.e. 1+) was identical to a 2+ and
3+ immunoscore. Additional and corresponding FISH analysis,
which would characterize the amplification status at a genomic
level, is only performed in a subset of studies [2,3,7]. A
strength of our study is that we present corresponding
immunohistochemistry and FISH results of a large number of
primary resected gastric carcinomas and carcinomas of the
gastroesophageal junction. More than half of the tumors in our
case collection of 347 specimens expressed varying degrees of
Her2. Ninety-six of them showed only weak immunoreactivity.
These cases would have been initially regarded “Her2
negative” by organ specific established scoring systems,
without further evaluation by FISH, following the
recommendations of the FDA/EMEA: Both institutions
recommend that only tumors with an immunoscore of 3+ and
tumors with 2+ and additional confirming in situ hybridization
should be labeled as Her2 positive and may be candidates for
trastuzumab therapy [20,24]. However, as discussed later, our
results indicate a certain biologic significance of even weak
Her2 immunoreactivity, and argue in favor of considering every
positive staining as an indicator for increased Her2 expression.
Her2 gene copy number showed a strong correlation with Her2
HSP90 and Her2 in Gastric/Gastroesophageal Cancer
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69098
expression and none of the Her2 negative tumors
(immunohistochemically score 0) was amplified. This is in line
with observations reported by others [2,3]. Like expected, Her2
expression or amplification was significantly more frequently
observed in tumors of intestinal type and better differentiation
[25]. Interestingly, a quarter of cases with a weak
immunoreactivity (score 1+) showed elevated Her2 copy
numbers and a subset of those displayed Her2-amplification.
These cases would have been missed following the FDA/
EMEA algorithm. Similar results have been reported recently,
recommending that not only Her2 immunohistochemically 2+,
but also 1+ gastric carcinomas should be evaluated by FISH
Figure 3.  Survival analysis for HSP90.  Univariate analysis
showed a strong association between HSP90 expression and
better prognosis (n=323, p=0.02).
doi: 10.1371/journal.pone.0069098.g003
analysis [26]. We observed a considerable number of
discordant cases with either Her2 amplification without
significant Her2 expression or vice versa. One explanation for
those differences in single cases might be intratumoral
heterogeneity of Her2, which has been reported to occur in a
significant percentage of gastric cancers [27,28]. We used the
same cores within our TMAs to assess both Her2 amplification
and expression, so that we can reliably exclude that different
tumor areas were chosen for immunohistochemical and FISH
Table 6. Multivariate Analysis for the subgroup of gastric
cancer patients (n=274).
factor Exp(B) 95.0% CI for Exp(B) p-value
  min max  
pTcategory 1.753 1.335 2.302 <0.001
pNcategory 1.283 1.108 1.487 0.001
cMcategory 1.556 1.041 2.327 0.031
Grading 0.715 0.447 1.144 0.162
Lauren 0.952 0.662 1.370 0.790
Resection-status 1.193 0.897 1.586 0.226
Her2 expression* 0.658 0.472 0.917 0.014
* Immunohistochemical score 1+,2+,3+
Table 7. Multivariate Analysis for the subgroup of non-
intestinal gastric and gastroesophageal carcinomas
(n=194).
factor Exp(B) 95.0% CI for Exp(B) p-value
  min max  
pTcategory 1.983 1.361 2.888 <0.001
pNcategory 1.36 1.156 1.599 <0.001
cMcategory 1.581 1.032 2.422 0.035
Grading 0.638 0.278 1.462 0.288
Resection-status 0.962 0.68 1.36 0.825
Her2 expression* 0.643 0.437 0.944 0.024
* Immunohistochemical score 1+,2+,3+
Figure 4.  Survival analysis for Her2 expression and Her2 status according to FDA/EMEA.  (A, B) Her2 expression, but not (C)
Her2 status according to FDA/EMEA was associated with better prognosis in univariate analysis.
doi: 10.1371/journal.pone.0069098.g004
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analysis, and rather consider our observation as a
tumorbiological true finding. The usage of TMAs for biomarker
analysis has been shown to be a powerful tool for analyzing
molecular markers in large tissue collections with the
advantage of homogenous reaction conditions, thus avoiding
false negative or false positive staining or hybridization results
due to technical reasons. However, some limitations have been
reported for molecular alterations with heterogeneous
expression patterns [29]. We used a TMA that was constructed
for the analysis of various biomarkers in gastric cancer [19].
The cores were randomly taken from various areas of the
tumors. The number of three cores is considered as
appropriate as a “rule of thumb” covering certain amounts of
heterogeneity, avoiding significant missing of information due
to loss of cores and allowing the inclusion of even smaller
tumors where no more TMA cores could be taken [29]. For
assessing Her2 in breast cancer, even less than three cores
have been reported to yield satisfactory results [30,31]. For
gastric cancer, there are several reports about the limitation of
assessing Her2 on superficially taken gastric cancer biopsies
due to intratumoral heterogeneity [28,32,33]. These studies
have pointed out the risk of false negative results due to
missing overexpressed clones. Most studies, though, regarded
an immunoscore of 1+ as negative [28,34]. Moreover,
intratumoral heterogeneity was reported to be more
pronounced for immunohistochemical detection than gene
amplification [33,34]. In our study we report any
immunoreactivity and have corresponding FISH data for every
tumor. The TMA cores were randomly selected covering
central and peripheral areas, and not only superficial areas of
the tumor. Moreover, the rate of Her2 “positive” cases lies
within the range reported in literature. At last, we chose the
proposed modification by Ruschoff et al. for assessing Her2 on
biopsies [20] for the immunohistochemical evaluation of Her2
on three TMA cores for each tumor, as we did in our previous
study on esophageal adenocarcinomas, which show similar
degrees of intratumoral heterogeneity of Her2 [21,35,36]. We
therefore consider our approach as appropriate for the purpose
of this explorative study, yet being aware of its potential
weakness and accepting a certain rate of both Her2 and
HSP90 false negative tumors. However, the relatively high
number of cases and the advantages of homogenous technical
conditions may equilibrate this limitation. In case of clinical
management, the use of TMAs may harbor the same risk of
missing information with consecutive incorrect therapeutic
decisions, and in that context investigation of whole tissue
sections should strongly be favored over the use of smaller
samples [20].
One interesting finding of our study was the considerable
rate of cases which were classified as polysome, i.e.
expressing elevated Her2 and CEP17 copy numbers below a
Her2/CEP17 quotient >2, which is the recommended definition
of Her2 amplification. Most of these cases were Her2 1+ or 2+.
In breast cancer, there are several publications, which direct
towards this yet unclear issue of Her2/CEP17 polysomy in
terms of determination of true Her2 status, and there is
increasing evidence that Her2/CEP17 polysomy represents
rather a phenomenon of co-amplification than true polysomy
[37–39].
Studies in breast cancer have also pointed out the limitations
of assessment of Her2 status by immunohistochemistry and
additional FISH. Immunohistochemistry has been described to
lack objectivity producing false-positive or -negative outcomes
due to interobserver variability, and both immunohistochemistry
and FISH are heavily dependent from technical issues such as
fixation and buffering [40,41]. However, major efforts with
respect to standardization of protocols and evaluation systems
have improved the rate of discordance between
immunohistochemistry and FISH results over the last years
[42–44]. In consequence, the estimated rate of incorrectly
assessed Her2 could be lowered to less than 5% [45]. The
evaluation system by the group around Ruschoff, which was
applied in the present work, takes into account the tumor
specific characteristics of Her2 staining in gastric cancer as
opposed to breast carcinoma, and represents a first step
towards standardization of Her2 assessment in this tumor
entity [20,23].
In literature there are congruent data about the rate of Her2
overexpressed and amplified tumors in gastric cancer but there
are still inconsistent results regarding any prognostic value of
Her2 in gastric carcinomas and adenocarcinomas of the
gastroesophageal junction [2,3,7]. A relatively high number of
papers advocating a negative impact of high Her2 levels on
survival are faced by a considerable amount of reports which
could demonstrate no or the opposite association of Her2 and
prognosis [5,46–48]. Using the definition of Her2 positivity
according to the FDA/EMEA criteria, which are widely applied
for assessing Her2 in gastric cancer, we would not have been
able to demonstrate any significant impact on prognosis. This
would also have been the case if we had considered an
immunoscore of 2+ and 3+ as criterion for Her2 expression,
like it was done in other immunohistochemical studies [48]. In
contrast, we observed that in our case collection any Her2
immunoreactivity – which also comprised a weak staining (1+)
– was associated with less aggressive tumor behavior and
turned out to be an independent significant favorable
prognostic marker both in the group of gastric carcinoma
patients and in the subgroup of non-intestinal type tumors,
which showed predominantly weak Her2 immunoreactivity.
Thus our results go in line with the few reports that
demonstrate a favorable prognostic impact of higher tumoral
Her2 expression, e.g. in esophageal adenocarcinomas [49].
Our observation of the prognostic impact of even weak Her2
immunoreactivity was unexpected, especially with regard to the
reports of others [3], but represents a highly reliable finding.
The large case collection it is based on comprises all stages of
primary resected tumors without pre- or perioperative
chemotherapy, originates from a single center in Germany and
can be regarded as representative in terms of gender and age
distribution of the patients, and the prognostic impact of
established parameters such as stage and grade. Moreover,
the strength of the present study is that every tumor was
analyzed for both Her2 expression and amplification, which is
comparably provided in recent studies only.
HSP90 and Her2 in Gastric/Gastroesophageal Cancer
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e69098
Our results speak in favor of a questioning attitude towards
the assessment of Her2 in gastric and gastroesophageal
carcinomas, like it has been adopted for Her2 in breast cancer
for almost two decades now [50].
Given the likelihood of increased application of trastuzumab
or other Her2 directed agents in gastric and gastroesophageal
cancer and the increasing number of publications about Her2 in
these tumors there will be clearly a need for an exact definition
of “Her2 status” that will cover yet unclear findings, like
polysomy, heterogeneity [27,28] and cases which lack
correlation between gene amplification and expression. This
definition should also cover predictive and potentially
prognostic value in order to provide a robust tool for further
therapeutic decisions in the treatment of gastric cancer
patients.
The stability and maturation of Her2 has been shown to be
mediated by so called “molecular chaperones” belonging to the
family of heat shock proteins (HSPs) [8,9]. HSPs are highly
conserved proteins, which are responsible for the accurate
folding of other proteins, thereby maintaining cellular integrity
and homeostasis [51]. There is evidence, that deregulation of
HSPs can be observed in malignant diseases – which may be
due to intrinsic antiapoptotic effects but also the altered
interaction with other oncogenic molecules [52,53]. One of the
most abundant cellular HSPs is HSP90. HSP90 interacts with a
large number of proteins, amongst them tyrosine kinases such
as Her2 and EGFR, where the interaction with the cytoplasmic
kinase domain leads to protein stabilization, but also signaling
proteins like Akt, K-ras, Raf-1, and mutated signaling proteins
like p53 and v-Src [54,55]. Therefore, HSP90 represents a
unique player in cellular homeostasis, and, in consequence, is
also regarded as a potential antitumoral target, especially in
Her2 positive tumors [55,56].
Inhibitors of HSP90 including Geldanamycin and its derivates
(e.g., 17-AAG and 17-DMAG) have already entered clinical
application [57–59]. In gastric cancer, preclinical studies of
HSP90 inhibitors alone and in combination with other
chemotherapeutic drugs or trastuzumab have already been
performed [10,60,61]. There are already promising data about
enhancing trastuzumab efficacy or even overcoming
trastuzumab resistance through HSP90 targeting for breast and
also gastric cancer in vitro and in vivo [12–14,62,63]. In
addition, dual Her2/HSP90 targeting drugs are being
developed [64].
We could verify the postulated association between Her2
and HSP90 expression on the tissue level, and could
demonstrate the prognostic role of Her2/HSP90. This points
towards a co-regulation of both molecules in vivo. Furthermore,
elevated HSP90 levels may render tumors susceptible for anti-
HSP90 directed therapy, a prerequisite met by one third of
cases of our case collective. Considering recent
pharmaceutical advances, either combination therapy with
conventional drugs could be a possible approach, or - with
regard to the high association with Her2 expression – also and
especially as additional approach to anti-Her2 therapy [65].
According to in vitro data [13,66], HSP90 inhibition should
result in enhancing the effect of therapy directed against Her2
or could even represent a possible tool for overcoming Her2
resistance. In human gastric cancer, various expression levels
of HSP90 can be detected, which may serve as a tissue-based
rationale for targeting this molecule. The impact of HSP90
expression on prognosis in gastric cancer patients, however,
remains currently unclear: there have been conflicting data
about an adverse or - like in our study – favorable influence of
HSP90 in gastric carcinomas in different populations and
collectives [17].
In summary, we could demonstrate immunoreactivity for
Her2 and corresponding gene amplification in a significant
subset of gastric and gastroesophageal adenocarcinomas. Our
results suggest a favorable prognostic impact of Her2
expression. This warrants further investigations regarding the
significance of Her2 non-amplified tumors showing Her2
immunoreactivity on the one hand and the definition of Her2
status in gastric cancers on the other hand. Moreover, the
correlation with the expression of Her2 chaperoning HSP90
may indicate a synergistic regulation of these molecules.
Targeting HSP90 with or without Her2 may offer additional
therapeutic options for gastric carcinoma treatment.
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